Form 4: Edgewise Therapeutics Insider Trades Common Stock

Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock and stock options on July 1, 2026.

Summary

• Alan J. Russell, Chief Scientific Officer and Director at Edgewise Therapeutics, Inc. (EWTX), engaged in several transactions on July 1, 2026.
• Russell acquired 130,352 shares of common stock at an average price of $0.45 per share and an additional 69,648 shares at an average price of $0.18 per share.
• Concurrently, Russell disposed of 130,352 shares at an average price of $39.406 and 69,648 shares at an average price of $39.4089.
• These transactions resulted in Russell beneficially owning 94,203 shares directly after the dispositions.
• The filing also notes the acquisition of stock options: 130,352 options with an exercise price of $0.45, expiring August 30, 2028, and 69,648 options with an exercise price of $0.18, expiring June 27, 2032.
• The acquisition of shares at lower prices and disposition at significantly higher prices suggests a profitable trade, potentially executed under a pre-arranged plan (Rule 10b5-1(c)).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the transactions show a profitable outcome for the insider, the disposition of a large number of shares by a key executive can be interpreted in various ways, though the 10b5-1 plan context suggests it was pre-planned.

Positives

• Acquisition of 130,352 stock options at $0.45 and 69,648 stock options at $0.18, indicating potential future upside at a low cost basis.
• The disposition of shares occurred at prices significantly higher than the acquisition prices of the options, suggesting a profitable outcome for the reported transactions.
• The reporting person continues to hold a direct beneficial ownership of 94,203 shares after the reported dispositions.

Negatives

• Disposition of a significant number of shares (200,000 total) at prices around $39.40, which could be interpreted as a lack of confidence in further short-term price appreciation by a key insider.
• The average sale prices are substantially higher than the exercise prices of the acquired options, indicating a realization of gains.

Risks

• The filing does not explicitly mention any risks or challenges.
• The disposition of a large number of shares by a key executive could be perceived negatively by the market, although the context of a 10b5-1 plan mitigates some of this concern.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of stock options with exercise prices significantly below the recent sale prices suggests a potential for future gains if the stock price appreciates.

Management Comments

• The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage their compensation and personal investments. The significant difference between acquisition and disposition prices for Edgewise Therapeutics' stock reflects the inherent volatility and potential for high returns in this industry.

Stakeholder Impact

• Shareholders: The disposition of shares by a key executive might be viewed with caution, although the 10b5-1 plan context suggests it was pre-planned and not an immediate reaction to negative news. The acquisition of options at low prices could signal future confidence if the company performs well.
• Employees: The existence of an Employee Stock Purchase Plan and stock options for executives aligns with common compensation structures in the industry.
• Management: The transactions reflect the executive's compensation and personal investment strategy.

Next Steps

• The reporting person may continue to acquire or dispose of securities as per their trading plan or other investment strategies.
• The company's future performance will dictate the value of the remaining stock options.

Key Dates

Keywords

Form 4, Insider Trading, Edgewise Therapeutics, EWTX, Stock Options, Common Stock, Beneficial Ownership, SEC Filing, Alan J. Russell, Chief Scientific Officer, Director, Rule 10b5-1